Ashwagandha, a herb with a history spanning thousands of years, is currently at a critical juncture. While revered for its traditional uses and backed by a wealth of scientific studies, it faces increasing scrutiny from European regulators. Concerns regarding potential abortifacient, endocrinological, immunological, and liver-related effects have sparked a wave of regulatory discussions. In response to this, Kerry has launched “Safeguard Ashwagandha,” a comprehensive website designed to be a central hub for accurate scientific information, data analysis, and regulatory updates related to ashwagandha’s safety. Dr. Mukesh Summan, Kerry’s Global Director of Toxicology, a highly respected expert in his field, emphasizes the urgent need to combat misinformation with credible scientific evidence. He highlights that while the scientific consensus overwhelmingly supports ashwagandha’s safety when used responsibly, a serious situation is unfolding where myths and unverified claims threaten to influence policy decisions. The platform is not just for Kerry but is an open invitation to other industry players to contribute their own research, aiming to protect ashwagandha for the entire industry.
The core issue, as Dr. Summan explains, is that many of the safety concerns being raised are based on poor quality studies, instances of adulterated products, or a lack of relevant expertise within the assessing food safety agencies. He specifically points to risk assessments from the Technical University of Denmark, which the industry largely dismisses as “hearsay and misinformation.” While acknowledging some reported cases of liver injury, Dr. Summan contextualizes these numbers, noting that they are extremely low given ashwagandha’s widespread and long-standing global use. He draws a powerful parallel to common medicines like paracetamol, which, despite having more documented cases of liver injury, are not banned but rather carry cautionary warnings. This perspective underscores the need for a balanced, evidence-based approach to assessing risk rather than resorting to outright bans, which he believes is a more credible and responsible path.
A significant point of contention revolves around the use of ashwagandha leaf extract, which some blame for reported toxicity issues. This is because, unlike the root, the leaf wasn’t traditionally used and has a smaller body of scientific evidence supporting its safety. This concern gained traction recently when India, the world’s leading producer of ashwagandha, issued an advisory restricting the use of ashwagandha leaves in food products due to “possible safety concerns… particularly withaferin A.” This move adds another layer of complexity to the ongoing debate. However, the scientific landscape is rapidly evolving. Kerry’s recent study on mice, for instance, provides compelling evidence that a blend of ashwagandha root and leaf is safe even at 19 times the standard dose. Furthermore, a special edition of Phytotherapy Research, spearheaded by Dr. Thomas Brendler and Professor Jo Barnes, is set to publish a comprehensive review of all ashwagandha safety concerns, promising to further clarify the scientific understanding.
Dr. Summan stresses that gold-standard clinical trials, preclinical studies, meta-analyses, and systematic reviews published in peer-reviewed journals consistently show ashwagandha to be safe when dosed appropriately. Yet, despite this robust scientific backing, countries like the Netherlands and the UK are expected to finalize their safety assessments soon, fueling anxiety within the industry. Kerry’s clients, Dr. Summan notes, are primarily concerned about their continued ability to source ashwagandha, rather than expressing significant safety concerns themselves. This highlights the real-world impact of escalating regulatory uncertainty. The “Safeguard Ashwagandha” initiative aims to cut through this uncertainty by providing a definitive, scientifically grounded resource.
The human element in this unfolding story is clear: a respected ancient herb, valued for its health benefits for millennia, is now under a microscope. While some voices raise alarms, often based on incomplete or misinterpreted data, a committed group of scientists and industry leaders are stepping up to defend its reputation. They’re not dismissing concerns outright but are advocating for a rational, scientific approach to risk assessment. It’s a call for calm amidst the noise, for evidence to trump fear, and for careful consideration of facts before making far-reaching regulatory decisions that could impact both consumers and an entire industry. The goal is to ensure that ashwagandha, a natural product with a long and beneficial history, continues to be accessible and safely enjoyed by those who can benefit from its traditional wisdom and modern scientific understanding.
Ultimately, the launch of Safeguard Ashwagandha represents a proactive effort to protect a valuable botanical ingredient. It’s a plea for thoughtful regulation, grounded in robust scientific data, rather than reactive decisions based on incomplete or sensationalized information. By providing a transparent and accessible repository of evidence, Kerry and its partners hope to guide regulatory discussions towards a balanced understanding of ashwagandha’s safety profile. This endeavor isn’t just about protecting a single ingredient; it’s about setting a precedent for how the botanical and natural products industry approaches scientific discourse, regulatory challenges, and the responsible dissemination of information to the wider public.